Health ministry probing irregularities in drug trials
May 10, 2012 - 7:24:41 PM
|
|
As per the rules, a new drug discovered outside India, should conduct trials in India on no less than 100 patients at three or four different hospitals. However, as many as 11 drugs out of these 39 never conducted any trial but were allowed to be sold. At least seven other drugs also flouted the norms of trial, but were allowed.
By IANS,
[RxPG] New Delhi, May 10 - The health ministry Thursday said it has already taken several steps to plug loopholes in the Central Drugs Standards Control Organisation, which has been pulled up by a parliamentary panel for allowing at least 33 drugs to be sold in India without proper trials.
The Parliamentary Standing Committee on Health, in its latest report, said at least 33 drugs were approved for sale in India during 2008-10 without conducting trials on Indian patients, and there was no scientific evidence to show that they are really effective and safe for them.
Reacting to this, the ministry said it was examining the report and would take appropriate action after the scrutiny.
After receipt of inputs from CDSCO - on the report and thorough its scrutiny, appropriate action will be taken by the ministry wherever required, the ministry said in a statement Thursday.
It also said the ministry had already initiated several steps to strengthen the CDSCO and streamline its functioning, but gave no details about the steps.
The panel in its report pointed out that there was an apparent nexus between drug manufacturers and experts, whose opinion matters so much in the decision making process at the CDSCO.
On an average, the DCGI - is approving one drug every month without trials. This cannot be in public interest by any stretch of imagination, the panel observed.
It also gave examples where the opinions of experts were based simply on personal perception.
In case of clevusine -, three experts - located at different places thousands of miles apart from each other, sent word to word identical letters of recommendation, it said pointing out one of many such cases.
Is the committee mistaken in coming to the conclusion that all these letters were collected by the interested party, it said, adding that the cases pointed to an apparent nexus.
The panel has also asked the ministry to conduct an enquiry and take appropriate action against the officials.
Among the 33 drugs which have been allowed without trial, the panel says, the ministry in the information given to the panel, missed name of two controversial drugs, 'ademetionine' and 'FDC of pregabalin'.
Pregabalin is not allowed to be sold in developed countries.
The panel also pointed out that out of randomly picked drugs which the panel wanted to check for the record of trials, the ministry could not provide the files of three drugs -- 'pefloxacin, lomefloxacin, and sparfloxacin'.
Strangely, all these cases also happened to be controversial drugs; one was never marketed in US, Canada, Britain, Australia, and other countries with well developed regulatory systems while the other two were discontinued later on, it added.
All three drugs are currently being sold in India and the panel has asked the ministry to reconstruct and review the files.
On the rest of the 39 random drugs, the panel found at least 13 drugs - which did not have permission for sale in any of the major developed countries.
The list includes drugs like Buclizine -, nimeslide injection -, pregabalin, which was missing from the government list for not having proper trial, and ofloxacin in combination with ornidazole, which is commonly used for gastrointestinal infections, among others.
As per the rules, a new drug discovered outside India, should conduct trials in India on no less than 100 patients at three or four different hospitals. However, as many as 11 drugs out of these 39 never conducted any trial but were allowed to be sold. At least seven other drugs also flouted the norms of trial, but were allowed.
In 64 percent of the drugs, no medical approval was taken.
|
Subscribe to Medical News Newsletter
|
|
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
